SNP | Chromosome:Positiona | Effect/other allele | Stageb | Sample size | EAF | OR (95% CI) |
p
|
---|
rs4969239 | 17:79010544 | G/A | Stage 1 | 8350 | 0.08 | 1.35 (1.2–1.52) | 1.40 × 10–6 |
Stage 2 | 3814 | 0.08 | 1.07 (0.83–1.39) | 5.78 × 10–1 |
Meta-analysis | 12,164 | 0.08 | 1.29 (1.16–1.44) | 4.18 × 10–6 |
rs9913477 | 17:79015698 | G/A | Stage 1 | 8350 | 0.06 | 1.44 (1.30–1.58) | 3.15 × 10–7 |
Stage 2 | 3815 | 0.06 | 0.86 (0.62–1.18) | 3.56 × 10–1 |
Meta-analysis | 12,165 | 0.06 | 1.33 (1.17–1.51) | 1.60 × 10–5 |
- CI, confidence interval; EAF, effect allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism
- aHuman Genome GRCh37/hg19 assembly, NT_010783.15
- bStage 1 model: Additive genetic models were adjusted for age group (by ~ 10-year intervals), WCHS study site, geographic region of residence, DNA source, and ancestry (PCs 5, 6 and 8 associated with cancer trait, p < 0.1); Stage 2 model: Additive genetic models were adjusted for age group (by ~ 10-year intervals), DNA source, and ancestry (PCs 1); Meta-analysis was performed in METAL [67]; heterogeneity I2 = 88.1 for rs9913477 and 58.1 for rs4969239